1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research & Forecasting
2.1. Research Methodology
2.1.1. Research Process
2.1.2. Research Framework
2.1.3. Research Reliability & Validity
2.1.4. Research Assumptions
2.2. Forecasting Methodology
2.3. Research Outcome
2.3.1. 360iResearch Competitive Strategic Window
2.3.1.1. Leverage Zone
2.3.1.2. Vantage Zone
2.3.1.3. Speculative Zone
2.3.1.4. Bottleneck Zone
2.3.2. 360iResearch FPNV Positioning Matrix
2.3.2.1. 360iResearch Quadrants
2.3.2.1.1. Forefront
2.3.2.1.2. Pathfinders
2.3.2.1.3. Niche
2.3.2.1.4. Vital
2.3.2.2. Business Strategy
2.3.2.2.1. Business Growth
2.3.2.2.2. Industry Coverage
2.3.2.2.3. Financial Viability
2.3.2.2.4. Channel Support
2.3.2.3. Product Satisfaction
2.3.2.3.1. Value for Money
2.3.2.3.2. Ease of Use
2.3.2.3.3. Product Features
2.3.2.3.4. Customer Support

3. Executive Summary
3.1. Outlook in the Monoclonal Antibody Therapeutics Market
3.2. Opportunities in the Monoclonal Antibody Therapeutics Market
3.3. Geographical Analysis in the Monoclonal Antibody Therapeutics Market

4. Premium Insight
4.1. Market Connectivity
4.2. Market Dynamics
4.2.1. Drivers
4.2.1.1. Growing adoption of monoclonal antibody therapeutics in cancer treatments
4.2.1.2. Increasing approvals of monoclonal antibodies
4.2.1.3. Rising use of monoclonal antibodies for the treatment of autoimmune diseases
4.2.2. Restraints
4.2.2.1. High cost of clinical research and development
4.2.3. Opportunities
4.2.3.1. Increasing product launches and regulatory support for the treatment of rare diseases
4.2.3.2. Increasing investment in R&D
4.2.4. Challenges
4.2.4.1. Variation in results from patient to patient
4.3. Porter’s Five Forces Analysis
4.3.1. Threat of New Entrants
4.3.2. Threat of Substitutes
4.3.3. Bargaining Power of Customers
4.3.4. Bargaining Power of Suppliers
4.3.5. Industry Rivalry
4.4. Industry Trends
4.4.1. Increasing Cases of Diseases Such as Cancer and Immunological Disorders
4.4.2. Rise in the Number of Companies Venturing into the Monoclonal Antibodies Space
4.4.3. Growing Pricing Pressure in the Monoclonal Antibodies Segment

5. Global Monoclonal Antibody Therapeutics Market, by Source
5.1. Overview
5.2. Market Sizing & Forecasting
5.3. Chimeric
5.4. Human
5.5. Humanized

6. Global Monoclonal Antibody Therapeutics Market, by End User
6.1. Overview
6.2. Market Sizing & Forecasting
6.3. Hospitals
6.4. Private Clinics
6.5. Research Institute

7. Global Monoclonal Antibody Therapeutics Market, by Application
7.1. Overview
7.2. Market Sizing & Forecasting
7.3. Autoimmune Diseases
7.4. Cancer
7.5. Hematological Diseases
7.6. Infectious Diseases
7.7. Ophthalmological Diseases

8. Global Monoclonal Antibody Therapeutics Market, by Geography
8.1. Americas
8.1.1. Overview
8.1.2. Market Sizing & Forecasting
8.1.3. Canada
8.1.4. Mexico
8.1.5. United States
8.2. Asia-Pacific
8.2.1. Overview
8.2.2. Market Sizing & Forecasting
8.2.3. China
8.2.4. India
8.2.5. Japan
8.3. Europe, Middle East & Africa
8.3.1. Overview
8.3.2. Market Sizing & Forecasting
8.3.3. France
8.3.4. Germany
8.3.5. United Kingdom

9. Competitive Landscape
9.1. 360iResearch FPNV Positioning Matrix for Global Monoclonal Antibody Therapeutics Market
9.2. Market Vendor Ranking Analysis for Global Monoclonal Antibody Therapeutics Market
9.3. Competitive News Feed Analysis for Global Monoclonal Antibody Therapeutics Market

10. Company Usability Profiles
10.1. AbbVie Inc.
10.1.1. Overview
10.1.2. Strategy
10.1.3. SWOT
10.1.4. Scorecard
10.2. Amgen Inc.
10.2.1. Overview
10.2.2. Strategy
10.2.3. SWOT
10.2.4. Scorecard
10.3. Bristol-Myers Squibb Company
10.3.1. Overview
10.3.2. Strategy
10.3.3. SWOT
10.3.4. Scorecard
10.4. Merck Sharp & Dohme Corp.,
10.4.1. Overview
10.4.2. Strategy
10.4.3. SWOT
10.4.4. Scorecard
10.5. Novartis International AG
10.5.1. Overview
10.5.2. Strategy
10.5.3. SWOT
10.5.4. Scorecard
10.6. Bayer AG
10.6.1. Overview
10.6.2. Strategy
10.6.3. SWOT
10.6.4. Scorecard
10.7. Biogen Inc.
10.7.1. Overview
10.7.2. Strategy
10.7.3. SWOT
10.7.4. Scorecard
10.8. Eli Lilly and Company
10.8.1. Overview
10.8.2. Strategy
10.8.3. SWOT
10.8.4. Scorecard
10.9. Envigo
10.9.1. Overview
10.9.2. Strategy
10.9.3. SWOT
10.9.4. Scorecard
10.10. F. Hoffmann-La Roche Ltd
10.10.1. Overview
10.10.2. Strategy
10.10.3. SWOT
10.10.4. Scorecard
10.11. GenScript
10.11.1. Overview
10.11.2. Strategy
10.11.3. SWOT
10.11.4. Scorecard
10.12. GlaxoSmithKline Plc
10.12.1. Overview
10.12.2. Strategy
10.12.3. SWOT
10.12.4. Scorecard
10.13. Johnson & Johnson
10.13.1. Overview
10.13.2. Strategy
10.13.3. SWOT
10.13.4. Scorecard
10.14. Pfizer Inc
10.14.1. Overview
10.14.2. Strategy
10.14.3. SWOT
10.14.4. Scorecard
10.15. Sanofi S.A
10.15.1. Overview
10.15.2. Strategy
10.15.3. SWOT
10.15.4. Scorecard

11. Appendix
11.1. Discussion Guide
11.2. Top Reports
11.2.1. Global Residential Washing Machine Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025
11.2.2. Global E-Paper Display Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025
11.2.3. Global Smart LED Lighting Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025
11.2.4. Global Sustainability and Energy Management Software Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025
11.3. Author Details